Cargando…

2250. Combination Vancomycin Plus Cefazolin for Methicillin-Resistant Staphylococcus aureus Bloodstream Infections

BACKGROUND: Combination β-lactam and vancomycin (VAN) prevent the emergence of resistance and result in synergistic antimicrobial activity against methicillin-resistant Staphylococcus aureus (MRSA) in vitro. We sought to provide clinical translation to these data and determine if patients with MRSA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jorgensen, Sarah C J, Trinh, Trang D, Zasowski, Evan J, Alosaimy, Sara, Melvin, Sarah, Bhatia, Sahil, Dhar, Sorabh, Mynatt, Ryan P, Pogue, Jason M, Rybak, Michael J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810267/ http://dx.doi.org/10.1093/ofid/ofz360.1928

Ejemplares similares

Combination Vancomycin/Cefazolin (VAN/CFZ) for Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Trinh, Trang D, et al.
Publicado: (2017)

1596. Impact of Vancomycin Area Under Curve on Persistent Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infections (BSI)
por: Alosaimy, Sara, et al.
Publicado: (2019)

1073. Predictors of Vancomycin Switch or Escalation in Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
por: Lagnf, Abdalhamid M, et al.
Publicado: (2018)

Monotherapy with Vancomycin or Daptomycin versus Combination Therapy with β-Lactams in the Treatment of Methicillin-Resistant Staphylococcus Aureus Bloodstream Infections: A Retrospective Cohort Analysis
por: Alosaimy, Sara, et al.
Publicado: (2020)

The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
por: Zasowski, Evan J, et al.
Publicado: (2019)

Corrigendum to: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
por: Zasowski, Evan J, et al.
Publicado: (2020)

Withdrawn as Duplicate: The Impact of Concomitant Empiric Cefepime on Patient Outcomes of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections Treated With Vancomycin
por: Zasowski, Evan J, et al.
Publicado: (2019)

Standardized Treatment and Assessment Pathway Improves Mortality in Adults With Methicillin-resistant Staphylococcus aureus Bacteremia: STAPH Study
por: Alosaimy, Sara, et al.
Publicado: (2021)

1227. Development of a Clinical Prediction Model for Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1061. Comparison of the Acute Physiology and Chronic Health Evaluation (APACHE) II Score and the Pitt Bacteremia Score to Predict Mortality in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1033. Unexpected Allies: Vancomycin and Cefazolin Combination Therapy in Methicillin-Resistant Staphylococcus aureus Bacteremia
por: Caniff, Kaylee E, et al.
Publicado: (2023)

2254. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Pseudomonas aeruginosa Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection
por: Zasowski, Evan J, et al.
Publicado: (2021)

Relationship Status between Vancomycin Loading Dose and Treatment Failure in Patients with MRSA Bacteremia: It’s Complicated
por: Ortwine, Jessica K., et al.
Publicado: (2019)

2391. Liposomal Vancomycin and Cefazolin Combinations for S. aureus Biofilms
por: Kebriaei, Razieh, et al.
Publicado: (2018)

Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia
por: Schweizer, Marin L, et al.
Publicado: (2011)

Role of Vancomycin Minimum Inhibitory Concentrations by Modified Population Analysis Profile Method and Clinical Outcomes in High Inoculum Methicillin-Resistant Staphylococcus aureus Infections
por: Trinh, Trang D., et al.
Publicado: (2018)

Open-Label Randomized Trial of Early Clinical Outcomes of Ceftaroline Fosamil Versus Vancomycin for the Treatment of Acute Bacterial Skin and Skin Structure Infections at Risk of Methicillin-Resistant Staphylococcus aureus
por: Claeys, Kimberly C., et al.
Publicado: (2019)

Combination of Vancomycin and Cefazolin Lipid Nanoparticles for Overcoming Antibiotic Resistance of MRSA
por: Bhise, Ketki, et al.
Publicado: (2018)

288 Lack of Synergy With Six Blood Isolates of Methicillin-Resistant Staphylococcus aureus (Vancomycin MIC of 2) Tested With Combinations of Vancomycin + Gentamicin, Vancomycin + Rifampin and Vancomycin + Cefazolin.
por: Long, Virginia, et al.
Publicado: (2014)

The Safety and Economic Impact of Cefazolin versus Nafcillin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections
por: Flynt, Lauren K., et al.
Publicado: (2017)

Risk Factors and Outcomes for Bloodstream Infections (BSI) Among Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
por: Rybak, Michael J, et al.
Publicado: (2017)

2384. Multidrug-Resistant Gram-Negative Infections Treated With Ceftolozane–Tazobactam: Impact of Delayed Initiation
por: Jorgensen, Sarah, et al.
Publicado: (2018)

2379. Multicenter Evaluation of Ceftazidime–Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah, et al.
Publicado: (2018)

1539. Dalbavancin, Vancomycin, and Daptomycin Alone and in Combination with Cefazolin Against Vancomycin Intermediate-Resistant (VISA) and Daptomycin Non-Susceptible (DNS) Staphylococcus aureus
por: Abdul-Mutakabbir, Jacinda, et al.
Publicado: (2019)

Evaluation of the INCREMENT-CPE, Pitt Bacteremia and qPitt Scores in Patients with Carbapenem-Resistant Enterobacteriaceae Infections Treated with Ceftazidime–Avibactam
por: Jorgensen, Sarah C. J., et al.
Publicado: (2020)

Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

Continued in vitro cefazolin susceptibility in methicillin-susceptible Staphylococcus aureus
por: Gern, Benjamin H., et al.
Publicado: (2018)

850. Outcomes of Patients Discharged on Parenteral Ceftriaxone Compared with Oxacillin or Cefazolin in Methicillin-susceptible Staphylococcal aureus (MSSA) Bloodstream Infections
por: Erik Connor, Lee, et al.
Publicado: (2019)

Dalbavancin, Vancomycin and Daptomycin Alone and in Combination with Cefazolin against Resistant Phenotypes of Staphylococcus aureus in a Pharmacokinetic/Pharmacodynamic Model
por: Abdul-Mutakabbir, Jacinda C., et al.
Publicado: (2020)

Risk Factors for Bloodstream Infections Among an Urban Population with Skin and Soft Tissue Infections: A Retrospective Unmatched Case-Control Study
por: Rybak, Michael J., et al.
Publicado: (2018)

266. Ceftriaxone Versus Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia
por: Mohamed, Adham, et al.
Publicado: (2020)

442. Risk Score for Vancomycin-Associated Acute Kidney Injury in Hospitalized Patients with Acute Bacterial Skin and Skin Structure Infections
por: Jorgensen, Sarah C J, et al.
Publicado: (2019)

The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA—Salvaging the Gold Standards with Combination Therapy
por: Morrisette, Taylor, et al.
Publicado: (2020)

251. High prevalence of the cefazolin inoculum effect in methicillin-susceptible Staphylococcus aureus causing bloodstream infections in a hospital network in Houston, TX
por: Pinargote-Cornejo, Paulette M, et al.
Publicado: (2020)

Diagnostic Stewardship: A Clinical Decision Rule for Blood Cultures in Community-Onset Methicillin-Resistant Staphylococcus aureus (MRSA) Skin and Soft Tissue Infections
por: Jorgensen, Sarah C. J., et al.
Publicado: (2019)

Vancomycin (VAN) Combinations with Β-Lactams (BLs) against Methicillin-Resistant Staphylococcus aureus (MRSA), Heterogeneous Intermediate-Level Resistance to Vancomycin (hVISA) and Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Tran, Kieu-Nhi, et al.
Publicado: (2017)

1811. Minimizing Time to Optimal Therapy for Enterobacteriaceae Bloodstream Infections: Is Organism Identification Enough?
por: Cwengros, Laura N, et al.
Publicado: (2018)

In vitro susceptibility to methicillin, vancomycin and linezolid of staphylococci isolated from bloodstream infections in eastern Turkey
por: Tekin, Alicem, et al.
Publicado: (2014)

Improvement in 100-m Sprint Performance at an Altitude of 2250 m
por: Linthorne, Nicholas P.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_61uhao48bho5scmh64pgrjrp9k